Please login to the form below

Not currently logged in
Email:
Password:

Amarillo Biosciences appoints Stephen Chen chair and CEO

He replaces Joseph Cummins, who will remain as the US biotech's chief operating officer

Amarillo Biosciences has selected Dr Stephen Chen, one of its directors, to take on the roles of CEO and chair.

Dr Chen takes over from Joseph Cummins, who will remain as the US biotech's president and chief operating officer.

Chen has been at Texas-based Amarillo since 1996, and has over 30 years' experience in the pharma and healthcare industry.

During this time he has held executive positions in R&D and business at several major pharma companies, including Burroughs Wellcome (now GlaxoSmithKline), Miles Pharmaceuticals (now Bayer), ICI America (now AstraZeneca), and Ciba-Geigy (now Novartis).

Since May 1992, he has been CEO of STC International, a US-based healthcare investment firm.

As CEO at Amarillo, Chen will lead operations at the company, which focus on research into the use of low-dose, oral interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough and HIV-related infections.

27th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics